Kinnate Biopharma (KNTE) News
Filter KNTE News Items
KNTE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KNTE News Highlights
- KNTE's 30 day story count now stands at 2.
- Over the past 12 days, the trend for KNTE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest KNTE News From Around the Web
Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.
13 Hot Penny Stocks To Buy According to Hedge FundsIn this article, we will take a look at the 13 Hot Penny Stocks To Buy According to Hedge Funds. To see more hot penny stocks, go directly to 5 Hot Penny Stocks To Buy According to Hedge Funds. The overall market optimism helped by expectations that the Fed might start cutting interest rates in […] |
Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsOrbiMed Advisors is part of a partnership interested in acquiring all of Kinnate Biopharma. Baker Brothers increased an investment in Madrigal Pharmaceuticals. |
OrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma IncOn November 13, 2023, OrbiMed Advisors LLC executed a significant stock transaction, reducing its holdings in Kinnate Biopharma Inc (NASDAQ:KNTE). The firm sold 450,000 shares at a trade price of $1.40, impacting its portfolio by a mere -0.01%. This move altered OrbiMed Advisors LLC's position in Kinnate Biopharma Inc to 7,559,729 shares, which now represents 0.19% of their investment portfolio and 16.00% of the company's outstanding shares. |
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesReported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023Previously announced strategic reprioritization with a focus on exarafenib combination in NRAS mutant melanoma, c-MET inhibitor KIN-8741 and brain penetrant CDK4 selectiv |
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's WhyKinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest gainers and losers this morning! |
Dell upgraded, Starbucks downgraded: Wall Street's top analyst callsDell upgraded, Starbucks downgraded: Wall Street's top analyst calls |
Early-stage cancer drug company to cut 70% of workforce, halt programsThe company, whose stock neared $49 within days of its December 2020 IPO, closed Monday at $1.70 per share. |
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringPromising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023 Completed exarafenib monotherapy dose expansion enrollment and cleared efficacious dose for KIN-3248, FGFR inhibitor; exploring strategic alternatives for both programs Paused KI |
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesReceived FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of $204.3 million as of June 30, 2023 anticipated to fund operations into early 2025 SAN FRANCISCO and SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the |